Instituting age- and sex-specific blood and plasma collection addresses one of healthcare's most pressing challenges: the rising costs and prevalence of chronic diseases in aging populations. These differentiations represent a fundamental paradigm shift in medicine — one that immediately translates regenerative research into accessible treatments benefiting both young donors and aging recipients, creating a sustainable model for community health within existing infrastructure.
In 2001 what is now the National Academy of Medicine published that sex is a fundamental biological variable in health, impacting everything from cellular biochemistry to disease presentation and response to treatment. In 2015, The National Institutes of Health identified sex as a biological variable in therapeutic interventions, and in 2025, the Food and Drug Administration concurred that consideration of sex differences are crucial to safety and optimal treatment outcomes.
In 1956 the first successful bone marrow transplant was performed. Since Kollman et al., was published in 2001, 18-35-year-old donors has been a cornerstone of the National Marrow Donor Program’s and World Marrow Donor Association’s bone marrow hematopoietic stem cell transplant (HSCT) donor recruitment because it was proven this this age group provided the best transplant outcomes.
A 2017–2018 Stanford/Alkahest PLASMA trial administered plasma from 18–30-year-old donors to patients with mild-to-moderate Alzheimer’s disease. The study found no serious adverse events and reported functional improvements in daily activities based on caregiver assessments.
The Department of Neurology and Neurological Sciences, Stanford University School of Medicine, published on June 15, 2020, that Young fresh frozen plasma from 18-25-year-old donors (yFFP) was safe, feasible, and well tolerated in people with Parkinson’s Disease (PD), without serious adverse effects and with preliminary evidence for improvements in phonemic fluency and stigma.
In 2021, The Neurology Center at the Texas Medical Center’s placebo-controlled study found that Young Plasma Infusions from sex-identified 18-25-year-old donors “Significantly Improve Clinical Symptoms and UPDRS Scores in Patients with Parkinson’s Disease.”
A November 11, 2024, study by Regenerative Health & Wellness in Houston, TX, revealed that 85% of joints experienced improvement in joint function and status after receiving plasma injections from sex-identified 18-25-year-old donors. Additionally, no patients experienced a decline in joint status from baseline or any adverse effects, further corroborating plasma from sex-identified young-adults as an effective and very low-risk treatment.
It was established that biological differences contribute to variations in the safety and efficacy of medical products, laying the foundation for sex-differentiated medical research.
The Institute of Medicine (now the National Academy of Medicine) declared that sex is a fundamental biological variable in health — one that impacts everything from cellular biochemistry to disease presentation and treatment response.
The NIH published findings confirming that sex influences how health and disease processes differ across individuals, informing preventive and therapeutic interventions in both sexes.
The FDA reaffirmed that biological differences contribute to measurable variations in the safety and efficacy of medical products.
Humans reach their biological peak between the ages of 18–25. Aging then progresses in "undulating" waves, with notable inflection points at ages 34, 44, 60, and 78. Critically, while red blood cells contribute to wound healing, plasma is the primary regulator of aging.
Plasma collection is detoxifying and healthy to undergo frequently. Its continually evolving composition means age-segmented collection provides distinct therapeutic profiles for different recipient needs.
Peak-biology plasma with maximum regenerative potential, collected for anti-aging therapies and research applications.
Anti-Aging PlasmaMature, high-quality whole blood with robust cellular profiles, directed to hospital systems and surgical supply chains.
Hospital Blood SupplyExperienced plasma with unique molecular signatures, sterilized and directed toward specialized pharmaceutical development.
Sterilized PharmaOur Mission
To advocate for affordable, population-level healthcare through a universally accessible multi-generational blood and plasma supply — employing merit-based basic income within specific demographic groups to optimize and encourage donations that sustain community health for all generations.